Follicular Thyroid Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Follicular Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Follicular thyroid carcinoma is a cancer that forms in follicular cells of the thyroid. Follicular thyroid cancer constitutes 10 to 15% of all thyroid cancer cases, making it the second most common. Unlike differentiated types, undifferentiated types are rare. Diagnosis of follicular thyroid carcinoma relies on pathologic confirmation of follicular cells devoid of the nuclear atypia seen in papillary thyroid cancer, considering factors like capsular and vascular invasion. Evaluation primarily centers on histological findings, with controversy arising due to variations among pathologists. Treatment modalities for follicular thyroid carcinoma hinge on the stage at presentation. Minimally invasive cases undergo thyroid lobectomy and isthmectomy, while invasive cases necessitate total thyroidectomy, radioiodine ablation, and thyrotropin-suppressing medications. Studies highlight a 2.1-fold increase in recurrence for those skipping radioiodine ablation, reinforcing the standard recommendation of total thyroidectomy followed by radioiodine radiation.
The Follicular Thyroid Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Follicular Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Follicular Thyroid Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Follicular Thyroid Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 20 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Follicular Thyroid Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Follicular Thyroid Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Follicular Thyroid Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AffyImmune Therapeutics IncAlphamab Oncology
AstraZeneca Plc
Beijing Scitech-MQ Pharmaceuticals Ltd
Bio-Thera Solutions Ltd
Exelixis Inc
Jiangsu Hengrui Medicine Co Ltd
Loxo Oncology Inc
MedGene Therapeutics Inc
Novartis AG
Osaka University
Pfizer Inc
Recordati SpA
Salubris Biotherapeutics Inc
Suzhou SmartNuclide Biopharmaceutical Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Verastem Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Follicular Thyroid Cancer reports